Skip to content

Author

Susan K. Keen

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Reappraisal of Surgical Threshold in Patients With Ascending Aortic Dilation

Background Indexing ascending aortic dimensions to height, rather than absolute diameters, may better identify at-risk ascending aortopathy (AA) patients who could benefit from earlier surgery. Objectives This study evaluated whether height-indexed aortic dimensions improve long-term risk stratification in AA patients who do not meet current surgical guidelines. Methods A total of 11,083 patients (68 ± 13 years, 79% men, 28% with bicuspid aortic valve, 2,196 with aortic surgery and 8,887 unoperated) with AA (4-5 cm) diagnosed on echocardiography (2010-2023) were included. Patients with syndromic aortopathy and acute aortic dissection/rupture at presentation were excluded. The maximum AA diameter, AA height index (AHI) (cm/m), and AA cross-sectional area-to-height (CSAH) (cm2/m) index were calculated. The primary outcome was mortality. Results The mean AA diameter, AHI, and CSAH were 4.4 ± 0.2 cm, 2.53 ± 0.3 cm/m, and 8.8 ± 1 cm2/m, respectively. At 6 ± 4 years, there were 84 (8.3%) deaths in the operated group and 1,058 (11.9%) in the unoperated group. There were 128 aortic dissections (1.4%) and 4 aortic ruptures (0.04%) in the unoperated group. Dividing the unoperated sample into a derivation cohort (n = 3,887), spline analysis demonstrated an increase in hazard for death in women with AA diameter ≥4.5 cm and in all patients with AHI ≥2.5 cm/m or CSAH ≥9 cm2/m. Validation in a separate cohort (n = 5,000) confirmed that AHI ≥2.5 cm/m and CSAH ≥9 cm2/m were associated with higher long-term mortality (both P < 0.05). Conclusions Indexing AA dimensions to height better identifies high-risk AA patients, particularly women, who fall below surgical criteria. Further studies are needed to determine if this cohort may benefit from earlier intervention at lower size thresholds.

Milind Y Desai, M. Abusafia, S. Jadam et al. · 1 citation
Review Jul 2026

Rewriting the sarcomere: Gene therapy approaches for hypertrophic cardiomyopathy from bench to bedside.

Hypertrophic cardiomyopathy (HCM) is a prototypical inherited cardiomyopathy with well-defined sarcomeric genetic underpinnings that make it an attractive target for molecular therapy. We review recent advances in gene-based approaches for HCM, including adeno-associated virus-mediate gene replacement, allele-specific silencing, and emerging gene editing strategies, and highlight the first demonstrations of in vivo target engagement and early clinical translation. Early-phase studies suggest that restoration of sarcomeric biology can favorably impact molecular and structural disease features. We further discuss key challenges related to immune responses, delivery efficiency, response durability, and patient selection that will shape the next phase of development. Together, these developments establish HCM as one of the important early models for cardiac gene therapy and highlight both the promise and complexity of translating genetic insight into durable clinical benefit.

Susan K. Keen, Barry Greenberg, M. Desai · 0 citations